Zacks Investment Research upgraded shares of Kura Oncology Inc. (NASDAQ:KURA) from a sell rating to a hold rating in a research note released on Wednesday morning.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Separately, Oppenheimer Holdings Inc. restated an outperform rating and issued a $16.00 target price on shares of Kura Oncology in a research report on Sunday, August 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $13.94.

Kura Oncology (NASDAQ:KURA) opened at 5.60 on Wednesday. The company’s market capitalization is $104.96 million. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The firm’s 50 day moving average price is $6.13 and its 200-day moving average price is $4.18.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. On average, equities analysts anticipate that Kura Oncology will post ($1.58) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC purchased a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology as of its most recent filing with the SEC. Hedge funds and other institutional investors own 43.63% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

5 Day Chart for NASDAQ:KURA

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.